Table 17 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS, for the subgroup in Netherlands
EQ-5D-3L at 6 months (mean) | EQ-5D-3L at 12 months (mean) | Difference between 12 and 6 months EQ-5D-3L (95% CI) | Effect size (Cohen’s D)a | n | % reporting 3L score increase | |
|---|---|---|---|---|---|---|
3L-VAS | ||||||
Improved | 0.80 | 0.90 | 0.10 (0.02 to 0.17) | 0.81* | 13 | 69 |
No change | 0.85 | 0.87 | 0.01 (− 0.02 to 0.06) | 0.12 | 32 | 41 |
Worsened | 0.75 | 0.74 | − 0.01 (− 0.12 to 0.09) | − 0.05 | 18 | 28 |
EQ-5D-5L at 6 months (mean) | EQ-5D-5L at 12 months (mean) | Difference between 12 and 6 months EQ-5D-5L (95% CI) | Effect size (Cohen’s D) | n | % reporting 5L score increase | |
|---|---|---|---|---|---|---|
5L-VAS | ||||||
Improved | 0.75 | 0.87 | 0.11 (0.02 to 0.20) | 0.78 | 13 | 62 |
No change | 0.82 | 0.85 | 0.03 (− 0.01 to 0.06) | 0.16 | 32 | 38 |
Worsened | 0.73 | 0.69 | − 0.04 (− 0.14 to 0.06) | − 0.14 | 18 | 39 |